Prostate cancer
Conditions
Interventions
Highly aggressive prostate cancer group :Nil
Non highly aggressive prostate cancer group :Nil
Sponsors
Department of Urology, Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients in the highly aggressive group must meet one of the following conditions: (1)Prostate cancer patients with clear lymph node metastasis from imaging studies; (2)Patients with bone metastasis or distant metastasis of prostate cancer have been suggested by imaging; (3)Prostate cancer patients whose clinical stage reaches or exceeds T3b or whose postoperative pathological stage reaches or exceeds pT3b; (4)Prostate cancer patients with pathological Gleason score greater than or equal to 9 in prostate biopsy or radical resection. 2. General prostate cancer group (non-highly aggressive group): other patients undergoing radical prostatectomy. 3. Patients who can collect peripheral blood samples, if the patient has children, can also collect peripheral blood samples of their children, regardless of whether they have children, and can cooperate with the detailed family history investigation, for patients with genitourinary system tumors or breast glands in the family members of the patients Collect peripheral blood samples for cancer patients; 4. The subject reads and fully understands the patient instructions, and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who have received bone marrow transplantation; 2. Suffer from other serious systemic diseases at the same time, which the investigator thinks may interfere with the treatment, evaluation and compliance of this test, including severe breathing, circulation, nerve, spirit, digestion, endocrine, immunity, urinary, etc. Systemic disease; 3. Patients judged by the investigator to be unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whole exome sequencing in highly aggressive prostate cancer group;Whole exome sequencing in non-highly aggressive prostate cancer group;Positive rate of incision margin, no recurrence time of Biochemistry after operation, urine control after operation, recovery rate of sexual function after operation, quality of life scale, survival time, endocrine adverse reactions;Clinical and pathological information; | — |
Countries
China
Contacts
Public ContactRen Shancheng
Department of Urology, Shanghai Changhai Hospital
Outcome results
None listed